Table 2. The treatment responses of the patients with Ph+ ALL.
| Total | 1st-generation TKI | 2nd-generation TKI | P-value | |
|---|---|---|---|---|
| Patients (N) | 77 | 45 | 32 | |
| 1st cycle CR rate (%) | 56 (72.7) | 32 (75.0) | 24 (71.1) | 0.706 |
| MMR rate after 1st induction | 22 (28.6) | 15 (33.3) | 7 (21.5) | 0.273 |
| 2nd cycle cumulative CR rate | 65 (84.4) | 39 (86.7) | 25 (81.3) | 0.518 |
| Cumulative MMR rate after 2nd chemotherapy | 47 (61.0) | 29 (64.4) | 18 (56.3) | 0.467 |
| Total CR rate before SCT | 72 (93.5) | 43 (95.6) | 29 (90.6) | 0.387 |
| Median time to CR (days) | 33.5 (11-113)) | 40 (11-113) | 27 (11-80) | 0.103 |
| MRD negative rate before SCT | 32 (41.6) | 20 (44.4) | 12 (37.5) | 0.542 |
| Time to MRD negative (days) | 60 (14-226) | 61 (14-163) | 60 (14-226) | 0.623 |
| Relapse before SCT | 22/72 (30.6) | 13/43 (30.2) | 9/29 (31.0) | 0.942 |
| TTP before SCT (days) | 135 (22-450) | 114 (22-450) | 201 (22-310) | 0.471 |
| DFS (days) | 263 (22-2134) | 247 (22-2134) | 280 (22-1094)) | 0.890 |
| OS (days) | 456 (59-2327) | 478 (71-2327) | 425 (59-1221) | 0.264 |
| CNSL | 20 (26.0) | 12 (26.7) | 8 (25.0) | 0.869 |
| T315 mutation/relapsed cases* | 5/17 (29.4) | 1/9 (11.1) | 4/8 (50.0) | 0.079 |
Abbreviations: CR, complete remission; MMR, major molecular response; MRD, minimal residual disease; TTP, time to progress; DFS, disease free survival; OS, overall survival; CNSL, center nervous system leukemia.
*17 out of 33 relapsed patients were available for ABL1 gene mutation detection.